Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
AVROBIO Inc
NASDAQ AVRO
Data sourced from
and
and
AVROBIO Inc Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2024: -0.17
AVROBIO Inc Free Cash Flow Per Share is -0.17 for the Trailing 12 Months (TTM) ending March 31, 2024, a 67.05% change year over year. Free Cash Flow per Share represents the amount of free cash flow generated per outstanding share of common stock. It provides insight into the per-share value of free cash flow and is commonly used in valuation analysis. A higher value suggests a potentially more favorable investment opportunity.
-
AVROBIO Inc Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2023 was -0.51, a 11.90% change year over year.
-
AVROBIO Inc Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2022 was -0.58, a 14.77% change year over year.
-
AVROBIO Inc Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2021 was -0.68, a -9.13% change year over year.
-
AVROBIO Inc Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2020 was -0.63, a 40.17% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: AVRO
| CEO | Mr. Geoff MacKay BSc |
| IPO Date | June 21, 2018 |
| Location | United States |
| Headquarters | Building 300, Cambridge, MA, United States, 02139 |
| Employees | 13 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Key trends
Similar companies
Hepion Pharmaceuticals Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email